Bacillus subtilis subso natto for producing natto kinase and application thereof

Abstract

The invention relates to a bacillus subtilis subso natto for producing natto kinase and application thereof. The bacillus subtilis subso natto (bacillus subtilis subso natto LNUB236), CCTCC No.: M 208156. The bacillus subtilis subso natto is subject to activation of culture, seed liquid and fermentation liquor are prepared, and the natto kinase is extracted. The invention relates to application ofthe natto kinase to preparing a health product for preventing and treating cerebral thrombosis. Constituents of the health product are proportioned by weight: lyophilized natto powder : natto kinase: natto kinase : evening primrose oil=1:2.0-3.0:1.0-1.5. The bacillus subtilis subso natto LNUB236 has high natto kinase yield, the highest enzyme activity is 431.455IU / ml in the event of production in a 30l fermenter, and the prepared natto kinase-containing health product has the advantages of high enzyme activity, obvious effect and no side effect.

Description

A subspecies of bacillus subtilis natto producing nattokinase and its application Technical field: The invention belongs to the field of biotechnology, and in particular relates to a bacillus subtilis natto subspecies capable of high-yielding nattokinase and an application thereof. A subspecies of Bacillus subtilis natto that produces nattokinase as claimed in the present invention is named: Bacillus subtilis subsp. Central deposit, No. CCTCCNO: M208156. Background technique: Thromboembolic disease is one of the leading causes of death and is the second most common disease after cancer today. At present, dissolving thrombus is an important means to treat this kind of diseases. The drugs used in clinical treatment today include streptokinase, urokinase, tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, Chemically modified plasmin-streptokinase activator complex, etc. These drugs all activate plasminogen in the blood to degrade fibrin ...

AI Technical Summary

Problems solved by technology

So far, the industry has not carried out large-scale production of nattokinase. The first reason is that no bacterial strain suitable for large-scale fermentation of high-yield nattokinase has been found to reach the standard for industrialized production; the second is the cost of large-scale fermentation of nattokinase Relatively high, the cost of developing nattokinase clinical standard drugs is expensive, and the cost of developing corresponding health care products is correspondingly low

Images